Buprenorphine 8 MG Sublingual Tablet — RxCUI 351265
RxNorm drug concept · Semantic clinical drug
RxCUI 351265
Semantic clinical drug · SCD
● Current RxNorm concept 36 FDA products
75 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI351265
Official nameBuprenorphine 8 MG Sublingual Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asbuprenorphine 8 MG (as buprenorphine HCl 8.64 MG) Sublingual Tablet; buprenorphine HCl 8 MG Sublingual Tablet
FDA products mapped36
Package NDCs mapped75
Reported Medicaid activity (SDUD)737,263 prescriptions · 51 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Buprenorphine Transdermal Patch: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- It is for severe, ongoing pain that needs around-the-clock opioid treatment when other options have not worked or are not enough. It is not for occasional, as-needed pain.
- Put one patch on clean, intact skin and leave it on for 7 days. Do not cut it or use a damaged one. Wait at least 3 weeks before using the same spot again.
- No. Heat makes your skin absorb more medicine, which could lead to overdose. Avoid heating pads, electric blankets, saunas, hot tubs, hot water and long sun exposure over the patch...
- The most common are nausea, headache, dizziness, constipation, sleepiness, vomiting and dry mouth. You may also have itching, redness or rash at the patch site. Call right away for...
🕸️ Concept Web — How Buprenorphine 8 MG Sublingual Tablet Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Buprenorphine 8 MG Sublingual Tablet
RxCUI 351265 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Buprenorphine
1819IN
-
Buprenorphine
-
Dose forms 8
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Buprenorphine Sublingual Tablet
371161SCDF -
Buprenorphine Oral Product
1151362SCDG -
Buprenorphine Pill
1151363SCDG -
Buprenorphine Sublingual Product
1295116SCDG -
Sublingual Tablet
317007DF -
Oral Product
1151131DFG -
Pill
1151133DFG -
Sublingual Product
1294706DFG
-
Buprenorphine Sublingual Tablet
-
Clinical & branded drugs 1
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Buprenorphine 8 MG
353391SCDC
-
Buprenorphine 8 MG
Showing up to 8 concepts per family — 10 of 10 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Buprenorphine 8 MG
SCDC · 353391 -
Buprenorphine Sublingual Tablet
SCDF · 371161 -
Buprenorphine Oral Product
SCDG · 1151362 -
Buprenorphine Pill
SCDG · 1151363 -
Buprenorphine Sublingual Product
SCDG · 1295116
📦 FDA Products & Package NDCs
36 products · 75 package NDCs
75 package NDCs map to RxCUI 351265 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00054-0176-13 | 30 TABLET in 1 BOTTLE (0054-0176-13) | Buprenorphine | Hikma Pharmaceuticals USA Inc. | 2009-10-08 |
| 00054-0177-13 | 30 TABLET in 1 BOTTLE (0054-0177-13) | Buprenorphine | Hikma Pharmaceuticals USA Inc. | 2009-10-08 |
| 00121-1019-30 | 30 TABLET in 1 BOTTLE (0121-1019-30) | buprenorphine hydrochloride | PAI Holdings, LLC dba Pharmaceutical Associates, Inc. and dba PAI Pharma | 2023-10-12 |
| 00121-2038-30 | 30 TABLET in 1 BOTTLE (0121-2038-30) | buprenorphine hydrochloride | PAI Holdings, LLC dba Pharmaceutical Associates, Inc. and dba PAI Pharma | 2023-10-12 |
| 00228-3153-03 | 30 TABLET in 1 BOTTLE (0228-3153-03) | Buprenorphine | Actavis Pharma, Inc. | 2015-04-10 |
| 00228-3156-03 | 30 TABLET in 1 BOTTLE (0228-3156-03) | Buprenorphine | Actavis Pharma, Inc. | 2015-04-10 |
| 00406-7012-03 | 30 TABLET in 1 BOTTLE (0406-7012-03) | Buprenorphine HCl | SpecGx LLC | 2026-01-19 |
| 00406-7018-03 | 30 TABLET in 1 BOTTLE (0406-7018-03) | Buprenorphine HCl | SpecGx LLC | 2026-01-19 |
| 00904-7154-04 | 30 BLISTER PACK in 1 CARTON (0904-7154-04) / 1 TABLET in 1... | Buprenorphine | Major Pharmaceuticals | 2009-10-08 |
| 00904-7155-04 | 30 BLISTER PACK in 1 CARTON (0904-7155-04) / 1 TABLET in 1... | Buprenorphine | Major Pharmaceuticals | 2009-10-08 |
| 31722-0870-30 | 30 TABLET in 1 BOTTLE (31722-870-30) | Buprenorphine HCl | Camber Pharmaceuticals, Inc. | 2026-01-12 |
| 31722-0871-30 | 30 TABLET in 1 BOTTLE (31722-871-30) | Buprenorphine HCl | Camber Pharmaceuticals, Inc. | 2026-01-12 |
| 42858-0501-03 | 30 TABLET in 1 BOTTLE (42858-501-03) | BUPRENORPHINE | Rhodes Pharmaceuticals LLC | 2017-10-25 |
| 42858-0502-03 | 30 TABLET in 1 BOTTLE (42858-502-03) | BUPRENORPHINE | Rhodes Pharmaceuticals LLC | 2017-10-25 |
| 50090-5805-00 | 30 TABLET in 1 BOTTLE (50090-5805-0) | BUPRENORPHINE | A-S Medication Solutions | 2021-10-15 |
| 50090-7559-00 | 30 TABLET in 1 BOTTLE (50090-7559-0) | buprenorphine hydrochloride | A-S Medication Solutions | 2025-05-27 |
| 50268-0128-15 | 50 BLISTER PACK in 1 BOX (50268-128-15) / 1 TABLET in 1 BLI... | Buprenorphine | AvPAK | 2024-03-19 |
| 50268-0129-15 | 50 BLISTER PACK in 1 BOX (50268-129-15) / 1 TABLET in 1 BLI... | Buprenorphine | AvPAK | 2024-03-19 |
| 58118-0176-08 | 30 TABLET in 1 BLISTER PACK (58118-0176-8) | Buprenorphine HCl | Clinical Solutions Wholesale, LLC | 2018-10-15 |
| 58118-0177-08 | 30 TABLET in 1 BLISTER PACK (58118-0177-8) | Buprenorphine HCl | Clinical Solutions Wholesale, LLC | 2018-10-15 |
| 58118-0460-08 | 30 TABLET in 1 BLISTER PACK (58118-0460-8) | Buprenorphine | Clinical Solutions Wholesale, LLC | 2025-02-03 |
| 58118-0502-08 | 30 TABLET in 1 BLISTER PACK (58118-0502-8) | BUPRENORPHINE | Clinical Solutions Wholesale, LLC | 2022-10-07 |
| 60687-0481-21 | 30 BLISTER PACK in 1 BOX, UNIT-DOSE (60687-481-21) / 1 TABL... | Buprenorphine | American Health Packaging | 2020-02-06 |
| 60687-0492-21 | 30 BLISTER PACK in 1 BOX, UNIT-DOSE (60687-492-21) / 1 TABL... | Buprenorphine | American Health Packaging | 2020-02-06 |
| 62756-0459-64 | 3 BLISTER PACK in 1 CARTON (62756-459-64) / 10 TABLET in 1... | Buprenorphine | Sun Pharmaceutical Industries, Inc. | 2016-02-17 |
| 62756-0459-83 | 30 TABLET in 1 BOTTLE (62756-459-83) | Buprenorphine | Sun Pharmaceutical Industries, Inc. | 2016-02-17 |
| 62756-0460-64 | 3 BLISTER PACK in 1 CARTON (62756-460-64) / 10 TABLET in 1... | Buprenorphine | Sun Pharmaceutical Industries, Inc. | 2016-02-17 |
| 62756-0460-83 | 30 TABLET in 1 BOTTLE (62756-460-83) | Buprenorphine | Sun Pharmaceutical Industries, Inc. | 2016-02-17 |
| 67296-2173-03 | 30 TABLET in 1 BOTTLE (67296-2173-3) | Buprenorphine | Redpharm Drug | 2016-02-17 |
| 70518-2014-00 | 30 TABLET in 1 BLISTER PACK (70518-2014-0) | Buprenorphine HCl | REMEDYREPACK INC. | 2019-04-12 |
| 71335-1154-00 | 120 TABLET in 1 BOTTLE (71335-1154-0) | BUPRENORPHINE | Bryant Ranch Prepack | 2024-04-03 |
| 71335-1154-01 | 90 TABLET in 1 BOTTLE (71335-1154-1) | BUPRENORPHINE | Bryant Ranch Prepack | 2019-03-15 |
| 71335-1154-02 | 60 TABLET in 1 BOTTLE (71335-1154-2) | BUPRENORPHINE | Bryant Ranch Prepack | 2019-03-15 |
| 71335-1154-03 | 30 TABLET in 1 BOTTLE (71335-1154-3) | BUPRENORPHINE | Bryant Ranch Prepack | 2019-07-22 |
| 71335-1154-04 | 20 TABLET in 1 BOTTLE (71335-1154-4) | BUPRENORPHINE | Bryant Ranch Prepack | 2024-04-03 |
| 71335-1154-05 | 7 TABLET in 1 BOTTLE (71335-1154-5) | BUPRENORPHINE | Bryant Ranch Prepack | 2020-01-16 |
| 71335-1154-06 | 28 TABLET in 1 BOTTLE (71335-1154-6) | BUPRENORPHINE | Bryant Ranch Prepack | 2021-06-28 |
| 71335-1154-07 | 1 TABLET in 1 BOTTLE (71335-1154-7) | BUPRENORPHINE | Bryant Ranch Prepack | 2024-04-03 |
| 71335-1154-08 | 12 TABLET in 1 BOTTLE (71335-1154-8) | BUPRENORPHINE | Bryant Ranch Prepack | 2024-04-03 |
| 71335-1154-09 | 14 TABLET in 1 BOTTLE (71335-1154-9) | BUPRENORPHINE | Bryant Ranch Prepack | 2024-04-03 |
| 71335-1163-00 | 120 TABLET in 1 BOTTLE (71335-1163-0) | Buprenorphine HCl | Bryant Ranch Prepack | 2024-05-17 |
| 71335-1163-01 | 90 TABLET in 1 BOTTLE (71335-1163-1) | Buprenorphine HCl | Bryant Ranch Prepack | 2019-03-21 |
| 71335-1163-02 | 60 TABLET in 1 BOTTLE (71335-1163-2) | Buprenorphine HCl | Bryant Ranch Prepack | 2019-04-24 |
| 71335-1163-03 | 30 TABLET in 1 BOTTLE (71335-1163-3) | Buprenorphine HCl | Bryant Ranch Prepack | 2019-04-01 |
| 71335-1163-04 | 20 TABLET in 1 BOTTLE (71335-1163-4) | Buprenorphine HCl | Bryant Ranch Prepack | 2024-05-17 |
| 71335-1163-05 | 7 TABLET in 1 BOTTLE (71335-1163-5) | Buprenorphine HCl | Bryant Ranch Prepack | 2024-05-17 |
| 71335-1163-06 | 28 TABLET in 1 BOTTLE (71335-1163-6) | Buprenorphine HCl | Bryant Ranch Prepack | 2024-05-17 |
| 71335-1163-07 | 1 TABLET in 1 BOTTLE (71335-1163-7) | Buprenorphine HCl | Bryant Ranch Prepack | 2024-05-17 |
| 71335-1163-08 | 12 TABLET in 1 BOTTLE (71335-1163-8) | Buprenorphine HCl | Bryant Ranch Prepack | 2024-05-17 |
| 71335-1163-09 | 14 TABLET in 1 BOTTLE (71335-1163-9) | Buprenorphine HCl | Bryant Ranch Prepack | 2024-05-17 |
Observed labelers:
Bryant Ranch Prepack (39) ·
Advagen Pharma Ltd (4) ·
Clinical Solutions Wholesale, LLC (4) ·
Sun Pharmaceutical Industries, Inc. (4) ·
A-S Medication Solutions (2) ·
Actavis Pharma, Inc. (2)
· +12 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.